Physician Assistant Program year 2025 Reported 2022–2025 Source: CMS Open Payments, 2026 publication

Stefanie Dubicki

Physician Assistant Stokesdale, NC Physician Assistant

NPI 1730723362 CMS profile 10751406

7779 Nc Highway 68 N Ste 2A, Stokesdale, NC 27357

Open in the dashboard

General payments

$5,227

117 records reported · program years 2022–2025

Research payments

$0

Paid to them · None reported · program years 2022–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Stefanie Dubicki of Stokesdale, NC is reported in the CMS Open Payments database as having received $5,227 across 117 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 92nd percentile of Physician Assistant profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

4 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $387 25
2024 General $478 20
2023 General $3,997 62
2022 General $365 10

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Stefanie Dubicki
  • Physician Assistant median
  • Middle half of Physician Assistant
  • National median

In program year 2025, general payments to Stefanie Dubicki were reported at $387. Among 68,903 Physician Assistant profiles paid that year, the median was $184 and the middle half received between $57 and $620.

Show as a table
Year Stefanie Dubicki Physician Assistant median Middle half National median
2019 $0 $34 $17–$122 $163
2020 $0 $33 $16–$78 $114
2021 $0 $132 $37–$438 $132
2022 $365 $155 $48–$522 $149
2023 $3,997 $167 $52–$557 $160
2024 $478 $178 $55–$600 $164
2025 $387 $184 $57–$620 $169

Breakdown

Who paid General payments · program years 2022–2025
  1. Boston Scientific Corporation $3,364 78 payments
  2. Medtronic, Inc. $1,563 26 payments
  3. Novo Nordisk Inc $73 3 payments
  4. SPR Therapeutics, Inc $48 2 payments
  5. ITI, Inc. $43 2 payments
  6. Relievant Medsystems, Inc. $38 1 payment
  7. Sumitomo Pharma America, Inc. $27 1 payment
  8. Salix Pharmaceuticals, a division of Bausch Health US, LLC $20 1 payment
  9. Axsome Therapeutics, Inc. $19 1 payment
  10. Pfizer Inc. $17 1 payment
  11. Other $15 1 payment

Every payment, record by record

What the payments were for General payments · program years 2022–2025
  1. Food and Beverage $3,120 107 payments
  2. Travel and Lodging $2,107 10 payments
Products named General payments · program years 2022–2025
  1. WaveWriter Alpha Prime 16 $2,674 32 payments
  2. INTELLIS ADAPTIVESTIM $1,366 23 payments
  3. General - Pain Management $164 15 payments
  4. Superion Indirect Decompression System $122 2 payments
  5. OSTEOCOOL RF ABLATION SYSTEM $112 1 payment
  6. AQUAMANTYS(TM) $71 1 payment
  7. Wegovy $50 2 payments
  8. SPRINT PNS System $48 2 payments
  9. CAPLYTA $43 2 payments
  10. Intracept $38 1 payment
  11. Other $321 15 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 21 drugs

Part D claims

2,237

Median for Physician Assistant: 241

Drug cost

$80,654

Median for Physician Assistant: $4,110

Branded share of claims

26.5%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Belbuca Buprenorphine Hcl Brand 25 $24,338
Buprenorphine Generic 68 $13,478
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 327 $7,377
Gabapentin Generic 461 $6,965
Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen Brand 183 $5,428
Methocarbamol Generic 258 $3,801
Lidocaine Generic 28 $3,688
Lidocaine-Prilocaine Lidocaine/Prilocaine Brand 20 $3,201
Pregabalin Generic 144 $2,141
Tizanidine Hcl Generic 125 $1,873

The 10 drugs with the highest cost, of 21 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 11 billing codes

Paid by Medicare

$32,520

Medicare's payments for the services billed

Medicare patients

224

Average age 72

Services billed

475

129 women, 95 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 75%
Chronic kidney disease 33%
Depression 33%
Diabetes 32%
Ischemic heart disease 29%
COPD 21%
Cancer 18%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

117 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant in North Carolina

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record